Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology

Beek, Nina van; Krüger, S.; Fuhrmann, Tarek; Lemcke, Susanne; Goletz, Stephanie; Probst, Christian; Komorowski, Lars; Zenzo, Giovanni Di; Dmochowski, Marian; Drenovska, Kossara; Horn, Michael P.; Jedličková, Hana; Kowaléwski, Cezary; Medenica, Ljiljana; Murrell, Dédée F.; Patsatsi, Aikaterini; Geller, Shamir; Uzun, Soner; Vassileva, Snejina; Zhu, Xuejun; Fechner, Kaï; Zillikens, Detlef; Stöcker, W.; Schmidt, Enno; Rentzsch, Kristin

doi:10.1016/j.jaad.2020.01.049

Cited by 31 publications

(20 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Please note that pemphigus may also be induced by non-Dsg autoantibodies ( 33 , 34 ). However, in >95% of pemphigus vulgaris/foliaceus patients, anti-Dsg autoantibodies are present ( 35 , 36 ). Thus, non-Dsg autoantibodies were not included in this table.…”

Section: Identification Of Distinct Autoantigens In Pemphigus and Pemmentioning

confidence: 99%

Milestones in Personalized Medicine in Pemphigus and Pemphigoid

et al. 2021

Self Cite

View full text Add to dashboard Cite

Pemphigus and pemphigoid diseases are autoimmune bullous diseases characterized and caused by autoantibodies targeting adhesion molecules in the skin and/or mucous membranes. Personalized medicine is a new medical model that separates patients into different groups and aims to tailor medical decisions, practices, and interventions based on the individual patient`s predicted response or risk factors. An important milestone in personalized medicine in pemphigus and pemphigoid was achieved by verifying the autoimmune pathogenesis underlying these diseases, as well as by identifying and cloning several pemphigus/pemphigoid autoantigens. The latter has become the basis of the current, molecular-based diagnosis that allows the differentiation of about a dozen pemphigus and pemphigoid entities. The importance of autoantigen-identification in pemphigus/pemphigoid is further highlighted by the emergence of autoantigen-specific B cell depleting strategies. To achieve this goal, the chimeric antigen receptor (CAR) T cell technology, which is used for the treatment of certain hematological malignancies, was adopted, by generating chimeric autoantigen receptor (CAAR) T cells. In addition to these more basic science-driven milestones in personalized medicine in pemphigus and pemphigoid, careful clinical observation and epidemiology are again contributing to personalized medicine. The identification of clearly distinct clinical phenotypes in pemphigoid like the non-inflammatory and gliptin-associated bullous pemphigoid embodies a prominent instance of the latter. We here review these exciting developments in basic, translational, clinical, and epidemiological research in pemphigus and pemphigoid. Overall, we hereby aim to attract more researchers and clinicians to this highly interesting and dynamic field of research.

show abstract

Section: Identification Of Distinct Autoantigens In Pemphigus and Pemmentioning

confidence: 99%

Milestones in Personalized Medicine in Pemphigus and Pemphigoid

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Both psoriasis and atherosclerosis share several pathophysiologic pathways including the abnormal regulation of Th1/ Th17 equilibrium and the overproduction of pro-inflammatory cytokines. 2,3 For this reason, we sought to explore any potential correlation between psoriasis severity and coronary artery disease (CAD) complexity.…”

Section: Correlation Of Psoriasis Severity With Angiographic Coronary Artery Disease Complexity: a Cross-sectional Studymentioning

confidence: 99%

“…Analyses included IIF on monkey oesophagus and human SSS as well as type VII collagen (Col7) ELISA (Euroimmun, L€ ubeck, Germany), immunoblotting with extracellular matrix of cultured keratinocytes (laminin 332), extract of human dermis (p200 protein and full-length Col7), recombinant laminin c1 and recombinant NC1 domain of Col7 as described previously. 2 All tests are accredited for routine diagnostic use (D-ML-13069-06-00).…”

mentioning

confidence: 99%

Epidermolysis bullosa acquisita: the most frequent pemphigoid disease in patients with dermal binding autoantibodies by indirect immunofluorescence microscopy on human salt‐split skin in Tehran, Iran

Daneshpazhooh

Fazlolahi

Mahmoudi

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Direct immunofluorescence on perilesional skin biopsy is considered the gold standard in diagnostic testing. 5 For autoimmune immunobullous testing, ELISA is available commercially as either EUROIMMUN or MBL kits. The EUROIMMUN Dermatology Profile ELISA (IgG) allows detection of the six most common autoantibodies in immunobullous conditions in one test run; BP180, BP230, Desmoglein 1, Desmoglein 3, envoplakin, collagen type VII.…”

Section: Introductionmentioning

confidence: 99%

“…Whilst studies on the validation of the BIOCHIP in different immunobullous conditions have been conducted, 5,[8][9][10][11][12] to the best of our knowledge there is no literature evaluating the EUROIMMUN Dermatology Profile ELISA compared to the BIOCHIP Mosaic 7 in an Australian cohort when used as a diagnostic screening method.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the EUROIMMUN Dermatology Profile ELISA to the novel BIOCHIP Mosaic 7 for the diagnosis of immunobullous skin disease

Simpson

Scardamaglia

Kok³

et al. 2021

Aust J Dermatology

View full text Add to dashboard Cite

Background:The BIOCHIP is an indirect immunofluorescence diagnostic investigation which identifies multiple autoantibodies with a mosaic panel of target antigen-specific substrates in a single incubation field. The EUROIMMUN Dermatology Profile ELISA allows simultaneous investigation of the six most important autoantibodies in bullous autoimmune dermatoses. Evaluation of the BIOCHIP Mosaic 7, compared to that of the EUROIMMUN Dermatology Profile ELISA, when used as a diagnostic investigation in pemphigus and pemphigoid, was undertaken in an Australian cohort. Methods:The serum of 27 patients was analysed including patients with pemphigus vulgaris (n = 10), pemphigus foliaceous (n = 4), bullous pemphigoid (n = 8), mucous membrane pemphigoid (n = 3) and negative controls (n = 2). Results of the BIOCHIP were compared with the EUROIMMUN Dermatology Profile ELISA, as well as with histology, direct immunofluorescence and indirect immunofluorescence.Results: In pemphigus vulgaris, sensitivity & specificity for the BIOCHIP Mosaic 7 were 100% and 94.1%, comparable to that of the EUROIMMUN Dermatology Profile ELISA with 80% sensitivity and 100% specificity. In bullous pemphigoid, sensitivity of the BIOCHIP was 87.5% and sensitivity of the EUROIMMUN Dermatology ELISA profile was 75%, whilst specificities for both diagnostic methods were 100% in our limited cohort. There was substantial or almost perfect concordance between the BIOCHIP Mosaic 7 and EUROIMMUN Dermatology Profile ELISA for pemphigus vulgaris and bullous pemphigoid. Conclusion:The BIOCHIP Mosaic 7 is a rapid, reliable diagnostic investigation in pemphigus and bullous pemphigoid. Results indicate it is comparable to the EUROIMMUN Dermatology Profile ELISA, whilst also providing additional testing with salt split skin, on one field.

show abstract

Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology

Cited by 31 publications

References 22 publications

Milestones in Personalized Medicine in Pemphigus and Pemphigoid

Milestones in Personalized Medicine in Pemphigus and Pemphigoid

Epidermolysis bullosa acquisita: the most frequent pemphigoid disease in patients with dermal binding autoantibodies by indirect immunofluorescence microscopy on human salt‐split skin in Tehran, Iran

Comparison of the EUROIMMUN Dermatology Profile ELISA to the novel BIOCHIP Mosaic 7 for the diagnosis of immunobullous skin disease

Contact Info

Product

Resources

About